Work

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-113477

Authors: Julie Kanter, John F. Tisdale, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Markus Y. Mapara, Manfred Schmidt, Alexandra L. Miller, Francis J. Pierciey, Weiliang Shi, Jean-Antoine Ribeil, Mark C. Walters, Alexis A. Thompson

Institutions: Medical University of South Carolina, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, Children's Hospital of Philadelphia, University of Pennsylvania, Emory University, Columbia University, Bluebird Bio (United States), UCSF Benioff Children's Hospital, Northwestern University, Lurie Children's Hospital

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2906725115

Cites:

Cited by: 14

Related to: 10